MorphoSys AG operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MorphoSys AG with three other
miscellaneous service companies in Europe:
Innate Pharma S.A.
sales of 79.89 million Euro [US$88.47 million]
of which 100%
was Licensing Revenue),
(74.61 million Euro [US$82.62 million]
Oxford BioMedica plc
based in the United Kingdom
(£66.78 million [US$83.47 million]
of which 82%
During the year ended December of 2018, sales at
MorphoSys AG were 76.44 million Euro (US$84.65 million).
increase of 14.5%
versus 2017, when the company's sales were 66.79 million Euro.
The sales level in 2018 was fairly close to the level five years ago: in 2013, MorphoSys AG had sales
of 77.96 million Euro.
Sales of Proprietary Development saw an increase
that was more than double the company's growth rate: sales were up
204.0% in 2018, from
17.64 million Euro to 53.61 million Euro.
Not all segments of MorphoSys AG experienced an increase in sales in 2018:
sales of Partnered Discovery fell 53.6% to 22.83 million Euro.